Results from a recent study have demonstrated a significant reduction in depressive symptoms and suicidality using ketamine as a solo treatment.
Data from Lobe Sciences has demonstrated that combination therapy of psilocybin and N-Acetylcysteine is more effective than monotherapy for mTBI and PTSD.
Better Life Pharma has obtained its first set of data on its lead compound TD-0148A, a second-generation LSD derivative, with further preclinical studies underway to determine...
Delix Therapeutics has raised $70m in a Series A funding round which is expected to fund its drug discovery platform of novel neuroplasticity-promoting compounds known as...
A first-of-its-kind study will investigate the use of MDMA-assisted psychotherapy for the treatment of female Hypoactive Sexual Desire Disorder (HSDD).
Heroic Hearts UK research director Grace Blest-Hopley discusses the organisation’s groundbreaking study that will investigate the use of psilocybin for treating brain trauma in veterans.
Heroic Hearts UK CEO Keith Abraham discusses his journey to setting up the organisation which aims to help veterans living with PTSD.
Mind Medicine has presented its novel findings on LSD and psilocybin from several ongoing studies.
An Italian cannabis referendum could potentially lead to the decriminalisation of psychotropic substance cultivation, such as cannabis and mushrooms, for personal use if successful.
The successful completion of Phase I of the world’s first clinical trial investigating the use of DMT-assisted therapy could lay the foundation for a “new paradigm”...
Psychiatrist Dr Tiago Reis Marques discusses what new research findings on ketamine mean for treatment-resistant mental conditions such as major depressive disorder.
Mind Cure Health has joined the Digital Therapeutics Alliance in a bid to drive awareness and adoption of digital therapies.
